GlassScriptPhysician profile
Suzy Melkonian
NPI 1730188152
$20,169.41
in general payments reported to CMS, 2019-2025
78 companies · $3,134 in 2025
The $3,134 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,722 · 2020: $1,987 · 2021: $3,616 · 2022: $3,055 · 2023: $3,601 · 2024: $2,054 · 2025: $3,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,001 · Education: $540 · Long Term Medical Supply Or Device Loan: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,000.57 |
| Education | $539.51 |
| Long Term Medical Supply Or Device Loan | $249.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,694.58 | 2019-2025 | |
| Genzyme Corporation | $1,683.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,362.62 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $1,209.67 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $1,063.01 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $1,037.19 | 2019-2025 | |
| Amgen INC. | $909.25 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Astrazeneca Pharmaceuticals LP | $797.14 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Seagen INC. | $770.64 | 2019-2025 | Adcetris, Tivdak, Tukysa |
| Karyopharm Therapeutics INC. | $592.54 | 2020-2025 | Xpovio |
| Lilly USA, LLC | $570.98 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $556.20 | 2019-2025 | |
| Celgene Corporation | $511.36 | 2021-2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $503.79 | 2020-2025 | Enhertu |
| Gilead Sciences, INC. | $470.70 | 2022-2025 | Trodelvy |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzy Melkonian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.